ERBB2 and breast cancer: During the first five years after tamoxifen therapy in ER-positive, HER2-negative, and nodal-positive luminal B patients with BC, high expression of SETD1A was associated with a high rate of relapse (AUC 0.67, P = 1.5E-02; Figure 1A).